| Name | Loxapine succinate |
| Description | Loxapine succinate (Loxapac), a D2DR and D4DR inhibitor, is utilized in schizophrenia. |
| In vitro | In rats, subcutaneous injection of Loxapine (0.3 mg/kg) induces general stiffness. In the rat brain, administering Loxapine (5 mg/kg) does not alter dopamine receptor density, but it reduces serotonin receptor density. |
| In vivo | Loxapine effectively facilitates the binding of [3H]ketanserin to 5-HT2 receptors in both the human frontal cortex (ki=6.2 nM) and the bovine frontal cortex (ki=6.6 nM). Additionally, in LPS-activated mixed glial cells, loxapine at concentrations of 0.2 μM, 2 μM, and 20 μM, successfully reduces the secretion of IL-1β and IL-2. |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
| Solubility Information | Ethanol : 2 mg/mL (4.48 mM)
DMSO : 82 mg/mL (183.9 mM)
|
| Keywords | 5-HT Receptor | antipsychotics | 5-hydroxytryptamine Receptor | Loxapine | serotonin | Loxapine succinate | Serotonin Receptor | Inhibitor | inhibit | Dopamine Receptor | schizophrenia | IL-2 | Loxapine Succinate | IL-1β |
| Inhibitors Related | Alverine citrate | Dapoxetine hydrochloride | Octopamine hydrochloride | Oxolinic acid |
| Related Compound Libraries | Pain-Related Compound Library | Bioactive Compound Library | Membrane Protein-targeted Compound Library | EMA Approved Drug Library | Anti-Cancer Clinical Compound Library | Drug Repurposing Compound Library | Anti-Cancer Approved Drug Library | Bioactive Compounds Library Max |
United States
